Telomir Pharmaceuticals Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. The company’s preliminary proxy statement is still under review by the Securities and Exchange Commission, delaying the annual meeting originally planned for December 30, 2025. Telomir has until February 23, 2026, to submit a compliance plan to Nasdaq and intends to hold the meeting promptly once the SEC review is complete, aiming to regain compliance and maintain its Nasdaq listing. The notice does not currently affect the trading or listing of the company’s shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-001170), on January 12, 2026, and is solely responsible for the information contained therein.